HOSPITAL UNIVERSITARIO QUIRÓNSALUD MADRID
Departamento
Maastricht University Medical Centre
Maastricht, HolandaPublicaciones en colaboración con investigadores/as de Maastricht University Medical Centre (10)
2020
-
Distribution of Prevalent and Incident Vertebral Fractures and Their Association with Bone Mineral Density in Postmenopausal Women in the Teriparatide Versus Risedronate VERO Clinical Trial
Calcified Tissue International, Vol. 106, Núm. 6, pp. 646-654
-
Efficacy of teriparatide compared with risedronate on FRAX®-defined major osteoporotic fractures: results of the VERO clinical trial
Osteoporosis International, Vol. 31, Núm. 10, pp. 1935-1942
-
Letter to the Editor: "Comparison of Teriparatide and Denosumab in Patients Switching from Long-Term Bisphosphonate Use"
Journal of Clinical Endocrinology and Metabolism
-
Partial Loss of USP9X Function Leads to a Male Neurodevelopmental and Behavioral Disorder Converging on Transforming Growth Factor β Signaling
Biological Psychiatry, Vol. 87, Núm. 2, pp. 100-112
-
Psychotropic medications and proton pump inhibitors and the risk of fractures in the teriparatide versus risedronate VERO clinical trial
Bone, Vol. 130
2019
-
Deleterious de novo variants of X-linked ZC4H2 in females cause a variable phenotype with neurogenic arthrogryposis multiplex congenita
Human Mutation, Vol. 40, Núm. 12, pp. 2270-2285
-
Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial
Archives of Osteoporosis, Vol. 14, Núm. 1
2018
-
Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial
Journal of Bone and Mineral Research, Vol. 33, Núm. 5, pp. 783-794
-
Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial
The Lancet, Vol. 391, Núm. 10117, pp. 230-240
-
Teriparatide vs risedronate for osteoporosis – Authors' reply
The Lancet